Botanical Oils Study to Determine Genetic Differences in the Way Your Body Processes Fats in Edible Oils

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-24

Study Completion Date

2015-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, controlled, cross-over clinical trial of borage oil vs soybean oil to determine whether the metabolism and/or impact of medium chain-polyunsaturated fatty acids (MC-PUFAs) in botanical oil supplements are changed in relationship to specific genotypes in a SNP (rs174537) strongly associated with FADS1 activity and PUFA metabolism.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects

NCT01145066

Diabetes Metabolic Syndrome x

COMPLETED PHASE2

A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism

NCT02366156

Hyperlipidemia

COMPLETED NA

Effects of a Dietary Supplement on Lipoprotein Lipids and Inflammatory Markers

NCT03118583

Healthy Volunteers

COMPLETED NA

Plant Sterol-Enriched Palm Oil to Improve Lipid Profile and Inflammation in Hyperlipidemic Individuals

NCT06595472

Hyperlipidemias

COMPLETED NA

Nuts and Oil Pilot Study

NCT04361617

Metabolic Syndrome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be a randomized, controlled, cross-over clinical trial of borage oil and soybean oil to determine whether the metabolism and/or impact of MC-PUFAs in botanical oil supplements are changed in relationship to specific genotypes in a SNP (rs174537) strongly associated with FADS1 activity and PUFA metabolism. Subjects previously genotyped at rs174537 will be given supplements and both blood PUFA (serum and erythrocyte membranes), urinary eicosanoids and eicosanoid release from whole blood (leukocyte generation) will be measured as biochemical determinants of genotype impact on supplement metabolism.

To evaluate the effect of genotype at the rs174537 locus on the metabolism of MC-PUFAs in borage and soybean oil to long chain polyunsaturated fatty acids (LC-PUFAs), including arachidonic acid, the investigators will utilize a double blind, randomized, crossover design. There will be three study groups based on the genotype of the healthy volunteer at rs174537. Individuals within each genotype will be consented and screened up to 8 weeks prior to randomization and the start of the intervention. Subjects will be randomized to begin with 4 weeks of either borage oil or soybean oil followed by an 8 week washout period, and then another 4 week period in which they take the second oil. Study visits will occur at 0, 2, and 4 weeks during each oil supplementation period, in addition to the consenting visit, for a total of 7 visits during the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Genetic Differences of Lipid Metabolism/Healthy Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GG genotype

Healthy participants with genotype GG at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.

Group Type OTHER

soybean oil and borage oil

Intervention Type DIETARY_SUPPLEMENT

Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.

GT genotype

Healthy participants with genotype GT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.

Group Type OTHER

soybean oil and borage oil

Intervention Type DIETARY_SUPPLEMENT

Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.

TT genotype

Healthy participants with genotype TT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.

Group Type OTHER

soybean oil and borage oil

Intervention Type DIETARY_SUPPLEMENT

Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

soybean oil and borage oil

Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Botanical oil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to give informed consent
* Must agree to adhere to dietary requirements during the entire study
* Be willing to participate for the whole study
* Be willing to not take PUFA supplements outside of those provided by the study
* Agree not to take interfering medications during the duration of the study
* Agree to allow samples to be stored for future use

Exclusion Criteria

* May not have diabetes, cancer, heart attack or vascular surgery within the past year, be diagnosed with heart disease, have uncontrolled high blood pressure, history of stroke, atherosclerosis, asthma, multiple sclerosis or chronic joint disease
* Gallbladder removal or gallbladder disease
* Use of tobacco products within the last six months
* Pregnancy or lactation
* Fasting triglycerides greater than 150 mg/dl
* Blood pressure greater than 130/90
* BMI equal to or greater than 30 or less than 19
* Fasting glucose greater than 125 mg/dl
* Have liver function values in the normal range
* Taking greater than 100 mg aspirin/day
* Taking NSAIDS or oral corticosteroids
* Taking montelukast-type allergy medications
* Having a pacemaker or a defibrillator
* Taking lipid lowering medications

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes